Profile
Sector:
HealthcareCountry:
United StatesIPO:
05 May 2000Next earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 2 min agoDividend
Analysts recommendations
Institutional Ownership
ANIP Latest News
PRINCETON, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution, 6.25 mg/15 mg per 5 mL.
PRINCETON, N.J. and ATLANTA, Sept.
PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the closing of its offering of $316,250,000 aggregate principal amount of 2.25% convertible senior notes due 2029 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In response to investor demand, ANI upsized the initial offering of $250,000,000 aggregate principal amount of notes to $275,000,000 and the initial purchasers fully exercised their option to purchase an additional $41,250,000 aggregate principal amount of the notes. The notes were issued pursuant to, and are governed by, an indenture, dated as of August 13, 2024, between the Company and U.S. Bank Trust Company, National Association, as trustee.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Lisa Wilson - IR Nikhil Lalwani - President, CEO & Director Christopher Mutz - SVP, Head, Rare Diseases Stephen Carey - CFO & SVP Conference Call Participants Les Sulewski - Truist Securities Gary Nachman - Raymond James & Associates Vamil Divan - Guggenheim Securities Oren Livnat - H.C. Wainwright & Co. Tim Chiang - Capital One Operator Good day, everyone, and welcome to today's ANI Pharmaceuticals, Inc. Second Quarter 2024 Earnings Results Call.
The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $0.93 per share. This compares to earnings of $1.28 per share a year ago.
ANIP has three 505(b)(2) NDA submissions under FDA review, including oral liquid terazosin, female testosterone drug, and oral liquid hydrochlorothiazide. Potential peak sales for Tezruly and hydrochlorothiazide in the US could exceed $500 million, while the female testosterone drug could generate $290 million in royalties. ANIP's revenue could reach $1.41 billion in sales and $290 million in royalties by 2028, with significant growth potential.
PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) and launched Naproxen Delayed-Release Tablets, USP. ANI's Naproxen Delayed-Release Tablets is the generic version of the reference listed drug (RLD) EC-Naprosyn®.
Conference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenue Adds two commercial assets ILUVIEN ® and YUTIQ ® with significant growth potential, expanding ANI's foothold in key strategic therapeutic area of ophthalmology Anticipated to drive high single digit to low double digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive thereafter Expected to generate additional $35 - $38 million in 2025 adjusted non-GAAP EBITDA inclusive of approximately $10 million in identified cost synergies; additional EBITDA contribution expected from accelerated growth of Purified Cortrophin ® Gel in ophthalmology Increased geographic diversification with Alimera's established ex-US footprint, including direct operations in Europe PRINCETON, N.J.
ANIP's potential royalty revenue from two upcoming drug applications could generate $415 million annually, not reflected in the current share price. ANI Pharmaceuticals' legal action against CG Oncology could result in royalties for Cretostimogene, potentially adding $125 million per year. The Company's female testosterone drug could generate royalties of $290 million per year, with potential for additional indications and international sales.
What type of business is ANI Pharmaceuticals?
ANI Pharmaceuticals, Inc. is a pharmaceutical company. Founded in 2001 in the state of Delaware. The headquarters are located in Baudette, Minnesota. The company's main activities include the development, production, and marketing of branded and prescription pharmaceuticals. A wide range of products produced includes medications used to treat various diseases, including cardiovascular, neurological, endocrine, infectious, gastrointestinal, and dermatological diseases, pain relievers, as well as medications for cancer treatment, hormones, and steroids. The company has three manufacturing facilities and its own laboratories that not only control the quality of the raw materials used but also engage in the development of pharmaceuticals.
What sector is ANI Pharmaceuticals in?
ANI Pharmaceuticals is in the Healthcare sector
What industry is ANI Pharmaceuticals in?
ANI Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry
What country is ANI Pharmaceuticals from?
ANI Pharmaceuticals is headquartered in United States
When did ANI Pharmaceuticals go public?
ANI Pharmaceuticals initial public offering (IPO) was on 05 May 2000
What is ANI Pharmaceuticals website?
https://www.anipharmaceuticals.com
Is ANI Pharmaceuticals in the S&P 500?
No, ANI Pharmaceuticals is not included in the S&P 500 index
Is ANI Pharmaceuticals in the NASDAQ 100?
No, ANI Pharmaceuticals is not included in the NASDAQ 100 index
Is ANI Pharmaceuticals in the Dow Jones?
No, ANI Pharmaceuticals is not included in the Dow Jones index
When was ANI Pharmaceuticals the previous earnings report?
No data
When does ANI Pharmaceuticals earnings report?
The next expected earnings date for ANI Pharmaceuticals is 08 November 2024